



OFF WALL STREET

Zoetis (ZTS)

DATE: 5/17/2026 | **SECTOR:** HEALTHCARE | **SETUP:** COMPETITION
MARKET CAP: \$31B | **ADV:** \$583M | **SHORT INTEREST:** 4%

Bull case

- Bulls view ZTS as the leading player in the secularly-growing Animal Health market, with the most comprehensive and innovative product portfolio, which has historically allowed the company to command a premium position and generate superior growth/margins relative to competitors
 - ZTS 3-year revenue growth CAGR ~5% vs. ELAN ~2%
 - ZTS 3-year avg. adj. GM ~71% vs. ELAN ~55%
- With shares having declined -48% since the company first reported a negative inflection in US Companion Animal revenue growth in 3Q25, the stock now trades at an all-time-low valuation (3.9x NTM EV/S and 10.6x NTM P/E vs. 5-year avg. 9.2x and 29.5x, respectively; ELAN currently 2.7x NTM EV/S and 18.7x NTM P/E)
- At this level, bulls believe the stock has more than sufficiently priced-in current weakness, which management attributes primarily to temporary industry/macro headwinds:
 - Declining vet visits and increased price-sensitivity amid broader macro weakness, intense promotional activity from new entrants, distributor/retail partner inventory de-stocking, tough comps
- Moreover, management has expressed confidence that the company can continue to grow revenue/earnings through this period, driven by:
 - Strong international and livestock growth, new product launches (LA Cytoint, Lenivia, Portela), new comprehensive cost and productivity program, investment in targeted DTC activity, and a robust pipeline (YE27-2028)

Short thesis

- We are skeptical of management's explanation that current weakness primarily reflects temporary macro headwinds, and of bullish expectations for a re-acceleration in revenue growth (from LSDs to MSDs) and continued gross margin expansion (~10-20bps p.a.)
 - We suspect intensifying competition is the primary driver of recent weakness in ZTS's US Companion Animal business (~45% of total revenues), with ELAN and MRK launching new blockbuster products that are rapidly gaining share in key growth categories that ZTS once dominated (e.g., Zenrelia, Befrena, and Numelvi in dermatology; Bravecto Quantum and Credelio Quattro in parasitocides)
 - ZTS's osteoarthritis mAb franchise is also flopping amid social media uproar over safety risks (seizures/death) and intensifying generic NSAID competition

- Meanwhile, ongoing vet/retail consolidation continues to reduce ZTS's pricing power at the same time as ELAN finally has a sufficiently comprehensive portfolio to disrupt ZTS's previous effective-monopoly on corporate accounts
- And broader macro weakness is only exacerbating ZTS's challenges given its 'premium' pricing/positioning
- In sum, the animal health market appears to have structurally changed for the worse: branded/generic competition is intensifying, price may be turning from a tailwind to a headwind, and market growth is softening significantly
- ZTS also appears to face an 'air pocket' over the next 12-18 months as near-term pipeline products are primarily reformulations of existing products that are unlikely to materially alter current competitive dynamics
- Moreover, despite significant multiple contraction to-date, ZTS still trades at a significant premium to ELAN on an EV/S basis, reflecting historically high margins that the company may struggle to sustain in this new environment

Risks

- Strength in international, livestock and diagnostics businesses more than offset continued US Companion Animal weakness
- Strong balance sheet/cash flow

All information contained herein is obtained by Off Wall Street Consulting Group, Inc. from sources believed by it to be accurate and reliable. However, such information is presented "as is," without warranty of any kind, and Off Wall Street Consulting Group, Inc. makes no representation or warranty, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Off Wall Street has strict policies prohibiting the use of inside information. We have also implemented policies restricting the use of experts. Among other things, Off Wall Street (1) does not hire expert networking firms; (2) does not hire as experts employees of those companies we research; and (3) specifically instructs consultants whom we hire to not provide us with inside information. All expressions of opinion are subject to change without notice, and Off Wall Street Consulting Group, Inc. does not undertake to update or supplement this report or any of the information contained herein.

Neither Off Wall Street Consulting Group, Inc. nor any of its employees or affiliated parties enter into short sale transactions (which includes short-oriented hedging strategies, such as buying put options) on any individual securities that are the subject of a "sell" recommendation by the company, at any time, either before or after the publication of a report. However, Off Wall Street Consulting Group, Inc. hereby discloses that we the company, or our officers and directors, employees and relatives, may now have and from time to time have, directly or indirectly, a long position in the securities assigned "buy" recommendations in reports issued by the company, and may sell or buy such securities at any time. Note that certain employees of Off Wall Street Consulting Group, Inc. are affiliated with a registered investment advisory firm, which does not short sell or buy puts on any individual-company securities, although it may have a long position in securities assigned "buy" recommendations in reports issued by the company.

Copyright 2026 by Off Wall Street Consulting Group, Inc.

N.B: Federal copyright law (Title 17 of the U.S. Code) makes it illegal to reproduce this report by any means and for any purpose, unless you have our written permission. Copyright infringement carries a statutory fine of up to \$150,000 per violation. We offer a reward of \$2,000 for information that leads to the successful prosecution of copyright violators.